Common Stock, Shares, Outstanding of Revance Therapeutics, Inc. from 31 Dec 2013 to 30 Sep 2024

Taxonomy & unit
us-gaap: shares
Description
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Summary
Revance Therapeutics, Inc. quarterly Common Stock, Shares, Outstanding in shares history and change rate from 31 Dec 2013 to 30 Sep 2024.
  • Revance Therapeutics, Inc. Common Stock, Shares, Outstanding for the quarter ending 30 Sep 2024 was 104,895,611, a 19% increase year-over-year.
Source SEC data
View on sec.gov
Common Stock, Shares, Outstanding, Quarterly (shares)
Common Stock, Shares, Outstanding, YoY Quarterly Change (%)

Revance Therapeutics, Inc. Quarterly Common Stock, Shares, Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2024 104,895,611 +17,082,296 +19% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 104,810,881 +16,860,894 +19% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 104,409,798 +20,392,590 +24% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 87,962,765 +5,576,955 +6.8% 31 Dec 2023 10-Q 07 Nov 2024 2024 Q3
Q3 2023 87,813,315 +5,526,447 +6.7% 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 87,949,987 +14,826,624 +20% 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 84,017,208 +12,253,443 +17% 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 82,385,810 +10,801,753 +15% 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 82,286,868 +10,448,091 +15% 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 73,123,363 +1,324,739 +1.8% 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 71,763,765 +352,376 +0.49% 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 71,584,057 +2,405,391 +3.5% 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 71,838,777 +5,251,064 +7.9% 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 71,798,624 +14,485,068 +25% 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 71,411,389 +14,385,235 +25% 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 69,178,666 +16,803,931 +32% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q3 2020 66,587,713 +22,479,306 +51% 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 57,313,556 +13,208,082 +30% 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 57,026,154 +13,021,496 +30% 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 52,374,735 +15,399,532 +42% 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 44,108,407 +7,116,285 +19% 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 44,105,474 +7,187,751 +19% 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 44,004,658 +7,261,811 +20% 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 36,975,203 +459,128 +1.3% 31 Dec 2018 10-K 26 Feb 2020 2019 FY
Q3 2018 36,992,122 +6,057,028 +20% 30 Sep 2018 10-Q 04 Nov 2019 2019 Q3
Q2 2018 36,917,723 +6,501,695 +21% 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 36,742,847 +6,613,607 +22% 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 36,516,075 +7,867,121 +27% 31 Dec 2017 10-K 28 Feb 2019 2018 FY
Q3 2017 30,935,094 +2,419,933 +8.5% 30 Sep 2017 10-Q 03 Nov 2017 2017 Q3
Q2 2017 30,416,028 +1,934,856 +6.8% 30 Jun 2017 10-Q 04 Aug 2017 2017 Q2
Q1 2017 30,129,240 +30,129,240 31 Mar 2017 10-Q 09 May 2017 2017 Q1
Q4 2016 28,648,954 +360,490 +1.3% 31 Dec 2016 10-K 02 Mar 2018 2017 FY
Q3 2016 28,515,161 +4,201,939 +17% 30 Sep 2016 10-Q 04 Nov 2016 2016 Q3
Q2 2016 28,481,172 +4,535,236 +19% 30 Jun 2016 10-Q 05 Aug 2016 2016 Q2
Q1 2016 0 -23,944,861 -100% 31 Mar 2016 10-Q 10 May 2016 2016 Q1
Q4 2015 28,288,464 +4,513,999 +19% 31 Dec 2015 10-K 28 Feb 2017 2016 FY
Q3 2015 24,313,222 +595,320 +2.5% 30 Sep 2015 10-Q 10 Nov 2015 2015 Q3
Q2 2015 23,945,936 +452,464 +1.9% 30 Jun 2015 10-Q 07 Aug 2015 2015 Q2
Q1 2015 23,944,861 +5,291,560 +28% 31 Mar 2015 10-Q 14 May 2015 2015 Q1
Q4 2014 23,774,465 +23,513,676 +9016% 31 Dec 2014 10-K 04 Mar 2016 2015 FY
Q3 2014 23,717,902 30 Sep 2014 10-Q 13 Nov 2014 2014 Q3
Q2 2014 23,493,472 30 Jun 2014 10-Q 13 Aug 2014 2014 Q2
Q1 2014 18,653,301 31 Mar 2014 10-Q 14 May 2014 2014 Q1
Q4 2013 260,789 31 Dec 2013 10-K 04 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.